SG12473

SG12473 is a recombinant humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. Developed by Hangzhou Shangjian Biotechnology, it is designed to function as a checkpoint inhibitor by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade prevents the suppression of T-cell activity, thereby restoring and enhancing the immune system's ability to identify and eliminate tumor cells. SG12473 is currently being evaluated in Phase I and Phase II clinical trials for a variety of advanced malignancies, including non-small cell lung cancer (NSCLC), Hodgkin lymphoma, melanoma, head and neck squamous cell carcinoma, and endometrial cancer, both as a monotherapy and in combination with other therapeutic agents.